Share Email Print

Proceedings Paper

Biodynamic imaging of therapeutic efficacy for canine B-cell lymphoma: preclinical trial results
Author(s): H. Choi; J. Turek; Z. Li; M. Childress; D. Nolte
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Biodynamic imaging uses coherence-gated dynamic light scattering to create three dimensional maps of intracellular dynamics in living tissue biopsies. The technique is sensitive to changes in intracellular dynamics dependent on the mechanism of action (MoA) of therapeutics applied in vitro to the living samples. A preclinical trial in the assessment of chemotherapeutic response of dogs with B-cell lymphoma to the doxorubicin-based therapy CHOP has been completed using biodynamic imaging. The trial enrolled 19 canine patients presenting with non-Hodgkin’s B-cell lymphoma. Biopsies were acquired through surgery or through needle cores. The time-varying power spectrum of scattered light after drugs are applied ex vivo to the biopsies represent biodynamic biomarkers that are used in machine learning algorithms to predict the patient clinical outcome. Two distinct phenotypes emerged from the analysis that correlate with patient drug resistance or sensitivity. Cross validation of the algorithms perform with an accuracy of 90% in the prediction of dogs that will respond to treatment. Biodynamic imaging has the potential to help select chemotherapy for personalized cancer care.

Paper Details

Date Published: 13 February 2018
PDF: 4 pages
Proc. SPIE 10493, Dynamics and Fluctuations in Biomedical Photonics XV, 1049304 (13 February 2018); doi: 10.1117/12.2291061
Show Author Affiliations
H. Choi, Purdue Univ. (United States)
J. Turek, Purdue Univ. (United States)
Z. Li, Purdue Univ. (United States)
M. Childress, Purdue Univ. (United States)
D. Nolte, Purdue Univ. (United States)

Published in SPIE Proceedings Vol. 10493:
Dynamics and Fluctuations in Biomedical Photonics XV
Valery V. Tuchin; Kirill V. Larin; Martin J. Leahy; Ruikang K. Wang, Editor(s)

© SPIE. Terms of Use
Back to Top